AbbVie |

AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs.

What section would you like to update?
  • Company Logo
  • Company Name & URL
  • Company Description
  • Founded Date
  • Company Status
  • HQ Address
  • Social Links
  • CEO Name & Picture
  • Competitor Set
  • Funding Events
  • Acquisition Events

If you'd like to make any changes to this portfolio we'd be happy to help. Please send info/sources to support@owler.com.


We'll be back up as soon as possible.

Visit owler.uservoice.com for FAQs

AbbVie Revenue, Funding, Number of Employees, Competitors and Acquisitions

ABBVIE CEO

Richard A. Gonzalez

Chairman & CEO

Richard A. Gonzalez

Approval Rating: 81/100

WEIGH-IN

How would you rate Richard A. Gonzalez as a CEO?

negative
You
neutral
You
positive
You

Founded:

2012

Headquarters:

North ChicagoIllinois

Status:

PublicNYSEABBV

Industry Sector:

Pharmaceuticals

Completeness:

100%

KEY STATS

Revenue

- -

What is AbbVie's revenue?

<1M

Employees

- -

How many people work at AbbVie?

Followers on Owler

- -

FOLLOW
UNFOLLOW

TOP COMPETITORS

Add a new competitor:

Thanks for your contribution!

Recalculating The Competitive Graph now...

ADD

AbbVie was founded in 2012 and its headquarters is located in North Chicago, Illinois, USA. AbbVie has $28.2B in revenue and 29000 employees. AbbVie's top competitors are Bristol Myers Squibb, Johnson & Johnson and Merck.

AbbVie Competitive Set

COMPANYLEADERSHIPCEO SCORE

EMPLOYEES
(ESTIMATED IF PRIVATE)

TOTAL FUNDING

REVENUE
(ESTIMATED IF PRIVATE)

LIKELY OUTCOME
AbbVieAbbVie ceo

Richard A. Gonzalez

Chairman & CEO

81/100
1Bristol Myers Squibb ceoBristol Myers Squibb

Giovanni Caforio

CEO

55/10023,700
$200M
2Johnson & Johnson ceoJohnson & Johnson

Alex Gorsky

Chairman & CEO

55/100126,400
$74.4B
3Merck ceoMerck

Kenneth C. Frazier

Chairman & CEO

69/10068,000
$48.4B
4AstraZeneca ceoAstraZeneca

Pascal Soriot

CEO

58/10059,700
$32.4B
5Amgen ceoAmgen

Robert A. Bradway

Chairman & CEO

60/10017,900$19M$22.8B
6Genentech ceoGenentech

Bill Anderson

CEO

63/10015,235$100M$18.3B
7Roche ceoRoche

Severin Schwan

CEO

85/1003,100
$49.6B
8Pfizer ceoPfizer

Ian C. Read

Chairman & CEO

68/10096,500
$51.9B

AbbVie Revenue History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

$

Community Estimate

UPDATE THIS

AbbVie Employee History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

Community Estimate

UPDATE THIS

AbbVie Leadership

NAMETITLESOCIAL MEDIA
Richard A. Gonzalez
Richard A. Gonzalez

Chairman & CEO

Chairman & CEO- -

AbbVie Acquisitions

COMPANY ACQUIRED ACQUISITION DATEAMOUNTDESCRIPTION
Stem CentRx, Inc.Stem CentRx, Inc.Apr 20165.8BStemcentrx researches, discovers, develops and commercializes therapies that cure and improve survival for cancer patients.
Pharmacyclics LLCPharmacyclics LLCMar 201521BPharmacyclics is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer and immune mediated diseases

AbbVie has acquired 2 companies.AbbVie's latest acquisition was Stem CentRx, Inc. in Apr 2016. Stemcentrx researches, discovers, develops and commercializes therapies that cure and improve survival for cancer patients.

AbbVie Investments

COMPANYDESCRIPTIONSTATUSINVESTMENT DATE/SOURCEROUNDEXIT DATEFOLLOW
Rodeo Therapeutics is a developer of novel small-molecular therapies for the treatment of inflammatory bowel disease and tissue regeneration.PrivateJul 24, 2017Series A
Aquinnah focuses on developing ribonucleic acid-binding proteins for the treatment of neurodegenerative diseases.PrivateApr 24, 2017Equity
Lodo Therapeutics is a drug discovery and development firm that focused on the creation of naturally derived novel therapeutics.Product/Brand/ServiceJan 10, 2016Series A
Alector engages in the discovery and development of antibody therapeutics for alzheimer's, dementia and mechanistically related diseases.PrivateJan 06, 2016Series D
Petra Pharma is a developer of novel small molecule inhibitors for the treatment of cancer and metabolic diseases.PrivateJan 05, 2016Series A
Lodo Therapeutics is a drug discovery and development firm that focused on the creation of naturally derived novel therapeutics.Product/Brand/ServiceDec 20, 2015Equity
MATTER is built for entrepreneurs and innovators in the fields of medical device, healthcare IT & medical diagnostics.PrivateNov 18, 2014Unattributed
AM–Pharma is a biopharmaceutical company developing proprietary recombinant human alkaline phosphatase therapeutics.PrivateSep 09, 2014Series E
Alvine Pharmaceuticals develops novel therapies for autoimmune diseases.PrivateMay 13, 2013UnattributedMar 01, 2016
Avaxia Biologics develops oral antibody therapeutics.PrivateDec 13, 2012Series B

SEE MORE

SEE LESS

AbbVie has acquired 2 companies.AbbVie's latest acquisition was Stem CentRx, Inc. in Apr 2016. Stemcentrx researches, discovers, develops and commercializes therapies that cure and improve survival for cancer patients.

AbbVie News

AbbVie: BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks* ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN'S DISEASE AT 52 WEEKSReuters
AbbVie: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?This blue chip biotech stock has big plans for investors.The Motley Fool
AbbVie: UPDATE 1-AbbVie to buy back $10 billion of shares, raises dividendFeb 15 (Reuters) - AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.Reuters
AbbVie: AbbVie shares the wealth with dividend boost $10bn in buybacksBioPortfolio
AbbVie: AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks24/7 Wall St.
AbbVie: BRIEF-Abbvie Increases Dividend, Announces New Stock Repurchase Program* ABBVIE INCREASES DIVIDEND AND ANNOUNCES NEW STOCK REPURCHASE PROGRAMReuters
AbbVie: AbbVie : Recognized as a FORTUNE 100 Best Company to Work For(4-traders.com) AbbVie is one of the 2018 FORTUNE 100 Best Companies to Work For, according to global research and consulting firm Great Place to Work and Fortune. This is AbbVie's first time on the list. 'Five years ago, we aspired to be recognized as a great company. Today, we are,' says Tim Richmond, senior vice president, Human Resources....http://www.4-traders.com/ABBVIE-12136589/news/AbbVie-Recognized-as-a-FORTUNE-100-Best-Company-to-Work-For-25999780/?utm_medium=RSS&utm_content=201802154-traders
AbbVie: AbbVie (ABBV) Showcases New, Late-Breaking Investigational Data at AAD MeetingAbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the 2018 American Academy of Dermatology (AAD) Annual Meeting (February 16-20, San Diego).StreetInsider
Press Release: AbbVie : Global Therapeutic Landscape of Hidradenitis Suppurativa Pipeline Review H1 2018PUNE, MAHARASHTRA, INDIA, February 12, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Hidradenitis Suppurativa - Pipeline Review, H1 2018"...EIN Presswire
AbbVie: AbbVie : FORTUNE Ranks AbbVie in the Top 10 Best Workplaces for Giving Back(4-traders.com) Today, Great Place to Work and FORTUNE named AbbVie to its annual listing of Best Workplaces for Giving Back. AbbVie took the No. 8 spot on the list, with 94% of AbbVie employees saying that they 'feel good about the ways we contribute to the community.' 'We celebrate and encourage the giving spirit of our...http://www.4-traders.com/ABBVIE-12136589/news/AbbVie-FORTUNE-Ranks-AbbVie-in-the-Top-10-Best-Workplaces-for-Giving-Back-25965133/?utm_medium=RSS&utm_content=201802094-traders

SEE MORE

SEE LESS

AbbVie Website History

Screengrabs of how the AbbVie site has evloved. (Click to expand)

AbbVie website history

Jan 2018

AbbVie website history

Jun 2017

AbbVie website history

Feb 2017

AbbVie website history

Nov 2016

AbbVie website history

Aug 2016

AbbVie website history

May 2016

AbbVie website history

Feb 2016

AbbVie website history

Nov 2015

AbbVie website history

Jul 2015

AbbVie website history

Feb 2015

AbbVie website history

Nov 2014

AbbVie website history

Aug 2014

AbbVie website history

May 2014

Owler has collected 13 screenshots of AbbVie's website since May 2014. The latest AbbVie website design screenshot was captured in Jan 2018.

AbbVie Headquarters

undefined company logo

1 N Waukegan Rd

North Chicago, Illinois 60064

1-847-932-7900

Driving Directions

google map

AbbVie Summary Information

AbbVie, Inc. (NYSE: ABBV) is engaged in the development, production, manufacture, and sale of pharmaceutical products. It is a research-based pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and chemically-synthesized pharmaceuticals, with a portfolio of more than 40 medicines in the market including the historically and therapeutically important HIV antivirals Norvir and Kaletra, the human monoclonal antibody, biopharmaceutical Humira for the treatment of autoimmune diseases, the humanized monoclonal Synagis for pediatric RSV infections, as well as Androgel, Lupron, and Synthroid. AbbVie operates more than a half dozen research and development facilities located in the United States, China, Japan, Singapore, and Germany, and more than a dozen manufacturing facilities located in North America, Europe, and Asia. As of December, 2015, the company employs more than 28,000 individuals worldwide and provides products to individuals in more than 170 countries. In October, 19, 2011, Abbott Laboratories announced plans to separate into two publicly-traded companies. The "new" Abbott Laboratories will specialize in diversified products including medical devices, diagnostic equipment, and nutrition products, while AbbVie will operate as a research-based pharmaceutical manufacturer. The separation became effective January 1, 2013 and AbbVie was officially listed in the New York Stock Exchange in January 2, 2013. In September, 2014, AbbVie and Infinity Pharmaceuticals announced that they have entered into a global collaboration to develop and commercialize duvelisib, Infinity's P13K inhibitor for the treatment of patients with cancer. On the same day, AbbVie and Calico announced that they had entered into a R&D collaboration intended to discover, develop, and bring into market new therapies for patients with age-related diseases, including neurodegeneration and cancer. In June, 2015, AbbVie and Halozyme Therapeutics announced that they had entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology. In March, 2015, AbbVie announced a definitive agreement in which it would acquire oncology firm Pharmacyclics and its flagship treatment for hematologic malignancies ibrutinib, marketed under the trade name Imbruvica. The transaction was completed in May, 2015 and Pharmacyclics' name was retained, and it operates as a subsidiary of AbbVie from its previous Sunnyvale, California headquarters. AbbVie developed adalimumab, which is marketed under the trade name Humira, a biopharmaceutical treatment for autoimmune diseases. AbbVie's portfolio of medicines include: AndroGel, Creon, Duodopa and Duopa, Kaletra, Lupron, Niaspan, Norvir, Sevoflurane, Synagis, Synthroid, TriCor and Trilipix, Viekira, and Zemplar. Some major industry competitors of AbbVie are Pfizer, Roche, and Merck. Richard A. Gonzalez, Chairman and CEO of AbbVie, Inc., has an 83% approval rating from Owler.

AbbVie's Chairman & CEO, Richard A. Gonzalez, currently has an approval rating of 81%. AbbVie's primary competitors are  Bristol Myers Squibb Johnson & Johnson Merck.

Visit the AbbVie website to learn more.